Sponsor Dossier
Medsurge Pharma
Sponsor Dossier for Medsurge Pharma. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: AMANTADINE
- Brand: AMANTAMED
- Brand: AMIKACIN
- Brand: AMOXICILLIN MLPL
- Brand: ANAGRELIDE
- Brand: ANAGRIDE
- Brand: ANIDULAFUNGIN
- Brand: ARGIPRESSIN
About
Medsurge Pharma is an Australian Private Company with ABN 48 169 759 068, registered in Victoria. The company operates under the trading names Medsurge Pharma and Medicianz Healthcare.
Portfolio
Medsurge Pharma has 107 brands on the ARTG, of which 70 are indexable brands with Product Information on file. Nine brands have at least one PBS-listed item, and three brands have PBAC outcomes on record. The portfolio includes notable brands such as Amantadine, Amikacin, Amoxicillin MLPL, Anagrelide, Anidulafungin, Argipressin, Atomed, Atracurium, and Azithromycin.
Therapeutic focus —
Neurology: 29 brands — Infectious Disease: 13 brands — Cardiology: 12 brands — Oncology: 12 brands — Pain & Anaesthesia: 10 brands — Haematology: 8 brands — Endocrinology: 8 brands — Gastroenterology: 5 brands — Dermatology: 3 brands — Ophthalmology: 3 brands — Urology: 1 brand — Pain Management: 1 brand — Other: 2 brands
PBS footprint
Nine brands in the Medsurge Pharma portfolio are PBS-listed, with the latest PBS schedule date touched on 1 May 2026.
Regulatory activity
The most recent PBAC outcome for Medsurge Pharma was recorded on 1 November 2025, with three brands holding PBAC outcomes on record. No brands have AusPARs on record.